Kornimate/medical-research-clean huggingface dataset:
body weight-based interval training in sedentary overweight and obese adults

Conditions: Body Weight Changes; Overweight and Obesity; Physical Activity

Summary: body-weight based interval training (it) performed 3 times per week will lead to reductions in abdominal adiposity and reduce overall body fat percentage in overweight and obese sedentary adults more effectively than moderate intensity continuous training (mict). body-weight interval training will improve exercise capacity (peak vo2) in overweight/obese adults.

participants will be randomly assigned to one of the two home-based exercise groups. the mict group is the standard care group and will be instructed to walk for 30 minutes, 5 days per week at a moderate intensity. the goal is to accumulate 150 minutes of continuous aerobic exercise each week. participants will be instructed on the use of the rating of perceived exertion (rpe) scale during baseline testing and will be instructed to reach an rpe of 12-16. a heart rate monitor will be worn to monitor exercise intensity. heart rate should reach \~70% of maximal heart rate. the it group will perform 5 body-weight exercises in three progressive phases. during the first 2 weeks the circuit will be completed twice, 30 second intervals, 90 seconds of rest. the exercises will be performed on 3 days of the week with at least one day of rest between exercise days (ideally monday, wednesday, friday). the number of repetitions will increase to a maximum of 4 while the interval and rest periods increase to a maximum of 45 seconds each. the total time spent performing intervals by week 8 will be 15 minutes. a 2 minute warm up and 3 minute cool down will be performed, such as jumping jacks or simply walking. a heart rate monitor will be used to measure exercise intensity. heart rate should reach approximately 90% of heart rate max during the intervals. participants will be instructed on the use of the rating of perceived exertion scale during baseline testing and will be instructed to reach an rpe of ≥17 during the high intensity intervals.

Eligibility criteria:
inclusion criteria: * adults 18-65 years of age * willing and able to provide informed consent * sedentary, overweight and obese adults (\<90 minutes of moderate intensity exercise) * bmi 25≤35 * able to safely begin an exercise program * have a smartphone, and willing and able to download and use the fitbit app exclusion criteria: * unable to provide informed consent. * known cardiovascular disease, or uncontrolled hypertension, * diagnosed type 1 or 2 diabetes * women who are pregnant or plan to become pregnant in the next 3-4 months * orthopedic injury/limitation or any other contraindications to exercise. * medications that cause weight gain (steroids, hiv-related medications, etc.), or glucose lowering medications
prostate irreversible electroporation study

Conditions: Prostate Cancer

Summary: conventional treatment options for localized prostate cancer include prostatectomy, radiotherapy and active surveillance. however, prostatectomy and radiotherapy carry certain degree of morbidity, including the risks of urinary incontinence, erectile dysfunction and injury to the structures in the proximity. active surveillance carries the risk of disease progression and psychological distress to the patients. focal therapy employs the concept of only destroying the significant lesion, resulting in disease cure and improved functional outcome. among the different options of focal therapy, irreversible electroporation has evolved over the past decades and can be a reliable treatment option. our study aims at assess the safety and effectiveness of such treatment in prostate cancer management.


Eligibility criteria:
inclusion criteria: * men aged between 40 - 85 years * visible index lesion(s) on mri * found to have localized prostate cancer after mri-usg fusion targeted biopsy or usg-guided template biopsy: clinical tumour stage \<=t2, or gleason score \<=7, or psa \<= 20 ng/ml exclusion criteria: * patients unfit for contrast mri exam * patients with active urinary tract infection * patients with bladder pathology including bladder stone and bladder cancer * patients with urethral stricture * patients with neurogenic bladder and/or sphincter abnormalities * patients who fail to give informed consent

Keywords: focal therapy
dietary fructose on microbiota and hepatosteatosis

Conditions: Hepatic Steatosis; Dietary Fructose Exposure

Summary: the consumption of sugar-sweetened beverages (ssb) has increased steadily over the past decades, resulting in the dramatic increase of fructose intake as it is one of the main ingredients of artificial sweeteners. recently, large epidemiological studies have documented the association between a high-fructose-diet and hepatic steatosis, and other metabolic disorders. so it is interesting for scientists to explore the underlying mechanism. this study aims to investigate the effect of dietary fructose and gut microbiota and the hepatosteatosis in healthy men. serum and fecal metabolomics will be investigated.

this is a single center, randomized, controlled study. 60 healthy men will be recruited according to the inclusion criteria. all subjects are randomly allocated to group a and group b, who orally takes 75g and 150g fructose daily respectively. subjects in group a will be instructed to drink fructose solution containing 75g fructose per day, and those in group b will be instructed to drink fructose solution containing 150g fructose per day. the intervention will last four weeks. the anthropomentric data will be collect with questionnaire and serum and fecal samples collected at baseline and the end of the intervention. the effect and mutual interaction of dietary fructose and microbiota will be explored. the effect of dietary fructose on hepatosteatosis will be investigated as well.

Eligibility criteria:
inclusion criteria: 1. healthy men aged from 18 to 40 (including both ends); 2. body mass index (bmi) ranges from 18.5 to 23.9 kg/m2 (including both ends); 3. the body weight has not changed dramatically in the past 3 months (±3kg); exclusion criteria: 1. subjects who have received antibiotic-related treatment, proton pump inhibitor treatment, or glucocorticoid hormone treatment within 1 month before enrollment; 2. subjects with diabetes or cardiovascular disease or other chronic diseases who require long-term medication; 3. subjects who suffered from an acute gastrointestinal diseases within the past month, or who have an history of chronic gastrointestinal disease or hepatitis; 4. subjects with a history of gastrointestinal surgery; 5. subjects with abnormal liver or kidney function, or severe cardiovascular diseases; 6. subjects with mental disorders or impaired cognitive function; 7. poor compliance; 8. participates enrolled in other clinical research at the same time; 9. other unsuitable occasions judged by clinicians..

Keywords: fructose microbiota nafld
search for restenosis markers in lower limb arteritis

Conditions: Restenosis; Lower Limb Arteritis

Summary: the initial hypothesis of this work is that the genesis and the evolution of the atheromatous plaque are partly controlled at the molecular level and in particular by the micrornas through their role as regulator of the genes. the study of the tissue and serum profile over time of specific micrornas involved in the regulation of atheromatous plaque correlated with clinical data and restenosis imaging will allow to define biological markers of restenosis in the patient with an arteritis of the lower limbs . this study is a pioneer in the field and it would be imprudent to conclude that a biomarker would be used clinically at the end of this work alone. nevertheless this study will make a major advance in this topic, in vivo intervention studies with inhibition or over-expression of microrna will obviously be necessary to confirm the use of these as biomarkers of arteritis of the lower limbs. regular assay of reliable biomarkers in arterial patients will ultimately suggest early management to best adapt surgical and medical treatment.


Eligibility criteria:
inclusion criteria: * any person to be surgically treated for arteritis on the femoropoplitetic stage, * affiliated to a social security scheme, * informed of the study and not opposed to it. exclusion criteria: * any person taken in charge for an arteritis on the femoro-popliteal floor refusing to participate in the study, * or not being able to express its consent.
beta-lactam pharmacokinetics in patients with infective endocarditis

Conditions: Infective Endocarditis

Summary: the recommended length of antibiotic treatment to patients with infective endocarditis is 4-6 weeks. all patients receive the same dosis except for those with renal impairment who receive a smaller dose. for beta-lactam antibiotics, a plasma concentration above the minimal inhibitory concentration (mic) for at least 50% of the time in a dosing interval maximize bactericidal activity. to estimate the time for which the antibiotic concentration is above the mic (t\>mic) and to see if there might be a relationship between the concentration of antibiotics and possible side-effects, toxicity and treatment failure, all patients admitted with infective endocarditis will be followed and have two blood tests withdrawn once a week during antibiotic treatment, an expected average of 5 weeks.

comorbidity is common in patients admitted with infective endocarditis and this may effect the pharmacokinetics of antibiotics. the same dose of antibiotics may therefore result in different plasma concentrations in different patients, and this might influence possible side-effects, toxicity and treatment failure. to investigate this further, all patients admitted with infective endocarditis, treated with beta-lactam antibiotics, will be followed and have two blood tests withdrawn once a week during antibiotic treatment, an expected average of 5 weeks. beta-lactam is administered every 6th hour. the first blood test will be withdrawn three hours after antibiotic infusion. the second blood test will be withdrawn right before the next antibiotic infusion. there is no intervention in the study, the results are observational. the results will contribute to assess the efficacy and quality of the treatment and help evaluate whether plasma concentration of antibiotics should be taken as a routine blood test every week in patients with infective endocarditis.

Eligibility criteria:
inclusion criteria: * patients admitted with infective endocarditis * treatment with beta-lactam antibiotics exclusion criteria: * under 18 years of age

Keywords: infective endocarditis therapeutic drug monitoring
intraoperative radiation therapy (iort) in dcis

Conditions: Breast Cancer; Ductal Carcinoma in Situ

Summary: the goal of this study is to examine the role of intraoperative radiotherapy (iort) in ductal carcinoma in-situ (dcis) and to improve the understanding of the clinical, radiographic, and patient-related impact of adopting iort.

with advances in technology and screening, the overdiagnosis and overtreatment of ductal carcinoma in situ (dcis) have increased. minimizing treatment toxicity and cost is a high priority area of research. intraoperative radiation therapy (iort)is a form of radiation where a single high dose of irradiation is applied to the tumor bed at the time of lumpectomy. its use has not been previously studied in dcis. proposed advantages include decreased toxicity to adjacent tissue and organs, reduction in healthcare costs, and improved quality of life. the investigators hypothesize that iort is a safe and patient-friendly alternative to whole breast irradiation.

Eligibility criteria:
inclusion criteria: * pathologically confirmed dcis of the breast * clinical ≤ 3.0 cm unifocal lesion * no clinical or pathological evidence of nodal involvement * operable dcis, suitable for breast conserving surgery * plans to administer irradiation to the breast only * eastern cooperative oncology group (ecog) performance status of 0-3, however grade 4 patients may be enrolled at the discretion of the treating radiation oncologist * must have had a diagnostic mammogram or mri performed within last 6 months * women of child-bearing potential must have a negative pregnancy test in accordance to institutional guidelines * women of child-bearing potential must agree to use adequate contraceptive precautions (defined as oral contraceptives, intrauterine devices, surgical contraceptives, or combination of condom and spermicide) from the time of negative pregnancy test through the radiation treatment period. * english or spanish speaking * able to sign informed consent * amenable to regular follow-up (according to research policies) for at least 5 years. exclusion criteria: * histologic or clinical evidence of invasive breast cancer * multicentric cancer in the ipsilateral breast as diagnosed by clinical examination, imaging, or pathologic assessment, not amenable to excision with negative margins with a single lumpectomy * synchronous bilateral breast cancer at the time of diagnosis * pathologic or imaging evidence of lymph node involvement * any severe concomitant disease that may limit their life expectancy to less than 5 years. * prior history of breast cancer or in-field radiation in the ipsilateral breast. * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * pregnant or breast feeding women

Keywords: dcis intraoperative radiation (iort) lumpectomy breast conserving surgery
oral n-acetylcysteine for protection of human nevi against uv-induced oxidative stress/damage in vivo

Conditions: Patients at Risk for Melanoma

Summary: this is a phase ii intervention to propose a new melanoma chemoprevention agent. the investigators believe oxidative stress/damage in nevi is a probable indication for melanoma risk, and propose that reduced melanoma risk in humans can be inferred by protection of nevi from ultraviolet light (uv)-induced oxidative changes. the investigators will 1) evaluate whether administration of nac around the time of uv exposure will reduce melanoma risk in high-risk patient populations with genetic susceptibility to uv-induced oxidative stress, and 2) examine key genetic variants that will identify which individuals are most likely to benefit from chemoprotection.


Eligibility criteria:
inclusion criteria: * must have at least 2 nevi (each \>6 mm diameter) not clinically suspicious for melanoma that can be biopsied. * must be able to receive informed consent and sign an approved consent form that conforms to federal and institutional guidelines. exclusion criteria: * the patient is a minor (\< 18 years old). * the patient cannot speak/understand english or spanish. (note: a spanish consent form and certified interpreter can be made available if needed) * the patient is pregnant. (note: all female patients who have not had a hysterectomy and are not post-menopausal (i.e. post-menopausal for 1 year and not of child-bearing potential) will have a urine pregnancy test.) * the patient is a prisoner, critically or mentally ill, or otherwise incapacitated or considered vulnerable. * the patient has history of allergic reaction to nac. * the patient has history of severe asthma. * the patient has been taking nac or any other oral antioxidant. * the patient has recent history (i.e., 3 months) of sunless tanning (tanning bed) or extensive sunburn.
relation between human epididymis protein 4 (he4) and endometrial pathology in patients with postmenopausal bleeding

Conditions: Postmenopausal Bleeding

Summary: all patients included in the study had single or multiple episodes of postmenopausal bleeding with an endometrial thickness of more than 5mm. full history, general and local examination were done. transvaginal ultrasound (tvs) was performed .the uterus was scanned in the sagittal plane. the double-layer et was measured at the widest point between the endometrial-myometrial interfaces.the level of he4 was measured. all women underwent hystrospopic guided endometrial biopsy. definitive management was later performed in the form of total abdominal hysterectomy, bilateral salpingo oophrectomy, with or without pelvic lymph nodal dissection and histopathological examination.

all patients included in the study had single or multiple episodes of postmenopausal bleeding with an endometrial thickness of more than 5mm. full history was taken , the number of episodes of postmenopausal bleeding, and previous investigations and current medications), general examination was performed and local examination was performed for all patients. transvaginal ultrasound (tvs) was performed .the uterus was scanned in the sagittal plane. the double-layer et was measured at the widest point between the endometrial-myometrial interfaces by using electronic calipers. if there was fluid in the uterine cavity it was recorded. suspected polyp was also recorded. for the level of he4: 5 ml of venous blood were withdrawn from all patients. the samples were left to clot. the separated sera were stored at -20˚ until all samples were obtained. frozen samples were allowed to reach room temperature prior to use. samples were then mixed thoroughly by gently inverting multiple times before analysis. he4 was quantitatively assayed using the enzyme immunoassay (eia) method (fujirebio diagnostics, inc. göteborg, sweden). the functional sensitivity of the he4 eia is ≤ 25pm. the analytical specificity is 100 ± 15%. all patients were then submitted to hysteroscopy under general anesthesia and endometrial biopsy. after hysteroscopy and biopsy, 2 patient proved to have cervical malignancy, 2 patients were unfit for open surgery, and another 6 patients did not show up after. these 10 patients were excluded from the study leaving 90 patients eligible for final analysis . definitive management was later performed in the form of total abdominal hysterectomy, bilateral salpingo oophrectomy, with or without pelvic lymph nodal dissection and histopathological examination.

Eligibility criteria:
inclusion criteria: * patients with single or multiple episodes of postmenopausal bleeding endometrial thickness ≥ 5mm exclusion criteria: * • history of other malignancies * patients on chemo and/or radiotherapy * patients on tamoxifen * patients unfit for surgical intervention * patients on hrt or other hormonal treatment
the effect of core stability exercises on idiopathic scoliosis in adolescent females

Conditions: Idiopathic Scoliosis

Summary: to evaluate the efficacy of core stability (cs) exercises on curve magnitude, posture, trunk deformity and quality of life in adolescent females with idiopathic scoliosis.

scoliosis is a disease in which the spine deviates or rotates laterally from its normal vertical line, and it can cause decreased spinal movement, weakening of muscles near the spine, reduced pulmonary function, respiratory dysfunction, chronic pain, and psychological suffering. scoliosis can be classified as idiopathic, congenital, neurofibromatosis, and neuromuscular. among these types of scoliosis, approximately 80% of patients with scoliosis have ais, which typically occurs around 10 years of age when healthy bone maturation occurs during adolescence. is is diagnosed when there are no known causes besides spinal deformity involving a lateral curvature with a cobb angle ≥10°. therapeutic approaches for is include surgical and conservative treatments. exercise therapy for is is considered important for maintaining spinal function when the cobb angle is \<20°. moreover, the effects of core stabilization exercise have been demonstrated recently for alleviating chronic lower back pain in patients, improving performance in athletes, and preventing sports injuries in athletes. based on this information, core stabilization exercise may be used effectively to improve neuromuscular imbalance, which is the cause of is. however, studies on the therapeutic effects of using core stabilization exercise in patients with ais are still lacking. accordingly, the objective of this study is to evaluate the efficacy of core stability exercises on curve magnitude, posture, trunk deformity, and quality of life in adolescent females with idiopathic scoliosis.

Eligibility criteria:
inclusion criteria: * their ages will be ranged from 10-19 years. * all adolescent females will be diagnosed as idiopathic scoliosis with s shape. * cobb angle on anterior-posterior radiograph will be used in the assessment of thoracic and lumbar cure of each patient in this study. * all adolescent females are not under any other treatment method for idiopathic scoliosis. * willingness and ability to comply with the study requirements and give informed consent. exclusion criteria: * patients with a history of rheumatologic, neuromuscular, cardiovascular, pulmonary, or renal diseases. * patients with congenital scoliosis or spinal deformity. * patients who had undergone surgical correction of the spine. * patients with a tumor. * enrollment in any other clinical trial during the time of this trial.
impact of iron injection on blood donation

Conditions: Iron Deficiency

Summary: this trial study and compare in blood and urinary matrices the impact of an iron injection on proteins involved in iron metabolism during a blood donation. the goal is to study the impact of an iron injection on detection markers of a blood donation in the anti-doping field

this study aim to investigate the impact of an iron injection on the proteins involved in iron metabolism during blood donation and to compare the blood and urinary matrix. a messenger rna profiling will be performed as well. the goal is to investigate the impact of iron injection on the markers of blood donation detection in the anti-doping field. the study will take place over a period of 8 weeks. volunteers will be randomly assigned to two groups. randomization will be provided by a software made for this purpose. an injection of 500 mg of iron in 250ml of saline solution or a placebo injection containing only the saline solution will be performed. standard blood sampling (in the arm) and finger prick blood sampling will be carried out. after that, 500 ml blood donation will be done. standard blood sampling and finger prick blood sampling will be performed before and after the donation. the study will be done in "simple blind", meaning that volunteers will not know if they get iron or saline solution. on the days of iron or saline solution injection and blood donation, blood sampling will be done up to 12 hours after the injection. after that, blood sampling will be scheduled up to 30 days after blood donation at a rate of once a day (except for the weekends).

Eligibility criteria:
inclusion criteria: * male between 20 and 35 yo * bmi between 18 and 30 * ferritin \< 50ug/l * transferrin saturation \< 20 if ferritin between 20 and 50ug/l exclusion criteria: * high level athlete * blood donation within 6 months before the study * liver disorder